Related Experiment Videos
Immunotherapy of cancer with genetically modified tumor vaccines
1Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA.
Abstract:
Distant metastasis is the major cause for therapeutic failures in Clinical oncology. Active immunotherapy in the adjuvant setting of patients with low tumor volume would contribute to further reduction of the remaining tumor and establish long-lasting immunity that could protect the patient from recurrence of disease. Studies employing rodent tumor models with little or no intrinsic immunogenicity have shown that genetically modified tumor cell preparations consisting of irradiated tumor cells transduced with and expressing cytokines, such as interleukin-2 (IL-2), IL-6, interferon-gamma (IFNgamma), or granulocyte-macrophage colony stimulating factor (GM-CSF), or co-stimulatory molecules, such as B7-I, were capable of inducing the regression of preexisting tumors and cure animals from their disease. Moreover, in some instances, the cured animals have retained immunological memory, as indicated by the fact that animals have resisted a second challenge with the parental tumor cells. Induction of potent immune responses in tumor-bearing animals against nonimmunogenic or weakly immunogenic tumors supports the view that active immunization of cancer patients deserves consideration despite lack of demonstrable immunogenicity in many human tumors.
Insights
Active immunotherapy using genetically modified tumor cells shows promise for reducing tumors and preventing recurrence. This approach can establish long-lasting immunity, even against non-immunogenic tumors, offering hope for cancer patients.
Area of Science:
- Oncology
- Immunology
- Cancer Research
Background:
- Distant metastasis is a primary reason for treatment failure in clinical oncology.
- Adjuvant immunotherapy in patients with low tumor burden can reduce residual disease and establish long-term immunity.
- Rodent models with poorly immunogenic tumors are used to study immunotherapy efficacy.
Purpose of the Study:
- To evaluate the potential of active immunotherapy in the adjuvant setting for cancer treatment.
- To investigate the ability of genetically modified tumor cell vaccines to induce anti-tumor immunity and prevent recurrence.
Main Methods:
- Genetically modified tumor cell preparations were created by transducing irradiated tumor cells with genes encoding cytokines (e.g., IL-2, IFNgamma, GM-CSF) or co-stimulatory molecules (e.g., B7-I).
- These modified cells were tested in rodent tumor models with low intrinsic immunogenicity.
- The induction of tumor regression, cure, and immunological memory was assessed.
Main Results:
- Genetically modified tumor cell preparations induced regression of existing tumors and cured animals in preclinical models.
- Cured animals demonstrated immunological memory, resisting subsequent challenges with parental tumor cells.
- Effective immune responses were generated against non-immunogenic or weakly immunogenic tumors.
Conclusions:
- Active immunotherapy, particularly with genetically modified tumor cells, is a viable strategy for managing residual cancer and preventing relapse.
- This approach can overcome the challenge of low tumor immunogenicity, establishing protective immunological memory.
- Further consideration of active immunization for cancer patients is warranted, even in the absence of strong pre-existing tumor immunogenicity.